Physician profile
Halyna Chykyda
NPI 1881073740
$3,923.52
in general payments reported to CMS, 2019-2025
16 companies · $855 in 2025
The $855 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $841 · 2020: $125 · 2021: $750 · 2022: $1,078 · 2023: $23.51 · 2024: $250 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,206.54 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $497.43 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $371.26 | 2021-2022 | |
| Biogen, INC. | $315.77 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $238.88 | 2019-2022 | |
| Novo Nordisk INC | $238.66 | 2021-2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $224.27 | 2022 | |
| Exact Sciences Corporation | $148.01 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sk Life Science, INC. | $125.00 | 2022 | |
| Amgen INC. | $124.96 | 2019 | |
| Acadia Pharmaceuticals INC | $124.77 | 2021 | |
| Neurelis, INC. | $116.83 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $115.76 | 2019 | |
| Pfizer INC. | $33.87 | 2021 | |
| Axonics, INC. | $23.51 | 2023 | Axonics |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halyna Chykyda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.